36 results about "Prostatic acid phosphatase" patented technology

Disclosed are methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, disclosed are assays that detect one or more markers selected from the group consisting of Prostatic acid phosphatase, Lactotransfenin, Soluble erythropoietin receptor, Von Willebrand factor, Soluble endothelial protein C receptor, and Beta-2-glycoprotein 1 as diagnostic and prognostic biomarkers in renal injuries.

Provided are methods for the detection and diagnosis of acute coronary syndrome or ACS. The methods are based on the discovery that abnormal levels of selected analytes in sample fluid, typically blood samples, of patients who are at risk are supportive of a diagnosis of ACS. At least two new biomarkers for ACS are thus disclosed, MMP-3 and SGOT. Altogether the concentrations of twelve analytes provide a sensitive and selective picture of the patient's condition, namely, whether the patient is suffering a heart attack. Other important biomarkers for ACS are described, including but not limited to IL-18, Factor VII, ICAM-1, Creatine Kinase-MB, MCP-1, Myoglobin, C Reactive Protein, von Willebrand Factor, TIMP-1, Ferritin, Glutathione S-Transferase, Prostate Specific Antigen (free), IL-3, Tissue Factor, alpha-Fetoprotein, Prostatic Acid Phosphatase, Stem Cell Factor, MIP-1-beta, Carcinoembryonic Antigen, IL-13, TNF-alpha, IgE, Fatty Acid Binding Protein, ENA-78, IL-1-beta, Brain-Derived Nerotrophic Factor, Apolipoprotein A1, Serum Amyloid P, Growth Hormone, Beta-2 microglobulin, Lipoprotein (a), MMP-9, Thyroid Stimulating hormone, alpha-2 Macroglobulin, Complement 3, IL-7, Leptin, and IL-6. Kits containing reagents to assist in the analysis of fluid samples are also described.

The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.

The invention provides a chemiluminescence immunoassay test kit of prostatic acid phosphatase, which belongs to the clinical blood detecting and assaying technique field. The test kit includes: 1) prostatic acid phosphatase calibrating article; 2) solid-phase carrier which is coated by monoclonal antibody against prostatic acid phosphatase; 3) monoclonal antibody against prostatic acid phosphatase which is labeled by enzyme; 4) chemiluminescence zymolyte on which the enzyme reacts; 5) washing liquid. Furthermore, the invention also provides a preparing method of the test kit which includes steps as following: the calibrating article is prepared; the solid-phase carrier is coated by the monoclonal antibody against prostatic acid phosphatase; the monoclonal antibody against prostatic acid phosphatase is labeled by the enzyme; the calibrating article, the enzyme labeled antibody and the chemiluminescence zymolyte above can be filled and packed through separate packing; and the finished produce is prepared after assembly. With security and reliability, the test kit has the advantages that the sensitivity is high, and the specificity is strong.

The present invention relates to the field of biomarkers. More specifically, the present invention relates to biomarkers useful in diagnosing aggressive prostate cancer. In one embodiment, a method for identifying patients as having or likely to have aggressive prostate cancer comprises the steps of (a) performing an assay on a biological sample obtained from the patient to detect fucosylated prostate specific antigen (PSA), transmembrane prostate androgen-induced protein, kallikrein-2, lipid phosphate phosphohydrolase 3, heparan-sulfate 6-O-sulfotransferase, prostatic acid phosphatase (PAP), nuclear RNA export factor 2, and protein POF1B; and (b) identifying the patient as having or likely to have aggressive prostate cancer if there is a statistically significant difference in the levels of fucosylated PSA, transmembrane prostate androgen-induced protein, kallikrein-2, lipid phosphate phosphohydrolase 3, heparan-sulfate 6-O-sulfotransferase, PAP, nuclear RNA export factor 2, and protein POF1B as compared to corresponding levels in a control sample that correlates to non-aggressive prostate cancer.

The invention provides tools for management of patients diagnosed with psoriatic arthritis, specifically, prior to the initiation of therapy with an anti-TNFα agent. The tools are specific markers and algorithms of predicting response to therapy based on standard clinical primary and secondary endpoints using serum marker concentrations. In one embodiment the baseline levels of VEGF, prostatic acid phosphatase, and adiponectin are used to predict the response at Week 14 after the initiation of therapy. In another embodiment, the change in a serum protein biomarker after 4 weeks of therapy is used such as MDC, lipoprotein a, and beta2-microglobulin.

The invention relates to preparation of a genetic recombinant protein, in particular to a prostate-cancer-specific PAP (prostatic acid phosphatase)-GM-CSF (granulocyte-macrophage colony-stimulating factor)-IL-6 (interluekin-6) genetic recombinant fusion protein and a preparation method thereof. The preparation method comprises steps of design and synthesis of primers, gene amplification and sequencing, construction of a recombinant vector pc DNA3.1-PAP-GM-CSF-IL-6, screening and identification of the recombinant vector pc DNA3.1-PAP-GM-CSF-IL-6, transfection of the recombinant vector pc DNA3.1-PAP-GM-CSF-IL-6 into an HEK293 cell line, as well as expression, separation, purification, concentration and determination of the PAP-GM-CSF-IL-6 recombinant fusion protein in the HEK293 cell line.

The invention relates to a preparation method of PAP/GM-CSF (prostatic acid phosphatase/grain macrophage-colony stimulating factor), in particular to a nucleotide sequence for encoding the PAP/GM-CSF.The amino acid sequence is encoded as the amino acid sequence shown in SEQ ID No.:1; preferably, the nucleotide sequence is shown in SEQ ID NO.:2. The invention also provides an expression carrier for high-efficiency expression of PAP/GM-CSF, engineering cell and a preparation method. The constructed PAP/GM-CSF has the advantages that when the PAP/GM-CSF is used for expressing the engineering cell, the expression amount is high, the expression is stable, and the like; the purifying technology is stable and reliable, the yield rate is high, and the large-scale production is convenient.

The invention relates to a TAT-PAP fusion protein. The TAT-PAP fusion protein is formed by protein transduction domain PTD of a trans-activator of transcription of human I type immunodeficiency virus HIV-I and prostatic acid phosphatase PAP. A preparation method of the TAT-PAP fusion protein comprises the following steps: selecting a pTAT-HA expression carrier containing Nco I and Xho I restriction enzyme cutting site sequences at the two ends respectively; synthesizing a pUC57-PAP carrier; carrying out double digestion on the pTAT-HA expression carrier and the pUC57-PAP carrier, and recycling respectively; obtaining a pTAT-PAP recombinant expression plasmid carrier; transforming the pTAT-PAP recombinant expression plasmid carrier into escherichia coli DE3 competent cells; and inducing expression of the fusion protein. The TAT-PAP fusion protein has the advantages that not only is the original penetrating power of TAT remained, but also activity of a foreign protein PAP is hardly influenced, so that the TAT-PAP fusion protein has a broad prospect in clinical application of a macromolecule protein medicine on diabetic neuropathic pain.

The present invention concerns conjugate compounds comprising a bisphosphonate covalently bonded to a prostatic acid phosphatase inhibitor and compositions comprising such conjugates. Methods for treating and inhibiting prostate cancer bone metastases, and determining whether a conjugate is useful for such treatment are also provided. In some instances, the bisphosphonate is alendronate, and it is covalently bonded to either tartaric acid or glyceric acid.

The invention relates to the technical field of biology, in particular to a system and a method for expressing and purifying recombinant protein with 3'-nucleotidase as a tag and application of the recombinant protein. The system is characterized in by comprising a 3'-nucleotidase nucleotide sequence and a protein over-expression vector, a 3'-nucleotidase nucleotide sequence added with a protease recognition site, a protease nucleotide sequence matched with the protease recognition site, a lysis solution containing at least one of Li<+> and Ca<2+> ions, an eluent of a chelating agent containing at least one of Li<+> and Ca<2+> ions, and PAP (Prostatic Acid Phosphatase) agarose gel. The system disclosed by the invention is a simple, high-efficiency and economic system for purifying a target recombinant protein.

The invention discloses an alkaloid compound separated from pumpkin seeds and an application thereof, which belong to the technical field of food and health products. The compound is extracted from pumpkin seeds and used for treating prostatic hyperplasia, the compound has obvious inhibition effect for three indexes of prostate wet weight, prostate index and prostate acidic phosphatase (PAP) whileeffect dosage is 250 mg/kg, has obvious inhibition effect for three indexes while effect dosage is 500 mg/kg, and has important application potential.

The present invention relates to the discovery of novel T cell epitopes of the human prostatic acid phosphatase (PAP) protein that is promiscuous for at least 15 different HLA-DR alleles. The invention also relates to compositions that contain one of the novel epitopes or a fusion peptide of such an epitope and a heterologous polypeptide. Further disclosed herein is the use of the epitopes or their fusion peptides, and compositions containing the epitopes or their fusion peptides.

The present invention provides a novel phosphatidic acid phosphatase gene. The object of the present invention can be solved by providing a nucleotide sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 7, SEQ ID NO: 4 or SEQ ID NO: 9, or SEQ ID NO: 5 or SEQ ID NO: 10; and an amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 6.

A method for testing compound for a therapeutic effect utilizing a non-human animal or cell having disruption in the prostatic acid phosphatase gene resulting in a decrease or absence in the activity or the level of prostatic acid phosphatase. The compound may be used for treating disorders related to unbalanced phosphatidylinositol phosphate cascade or signaling pathway. Diagnostic methods and methods for treating the disorders with therapeutic compounds or by gene therapy are also disclosed.

The invention belongs to the field of biological medicine, and particularly provides a sequence of a prostate acid phosphatase (PAP) resisting antibody and application of the prostate acid phosphatase (PAP) resisting antibody. The anti-PAP antibody disclosed by the invention has relatively high affinity with PAP or a fusion protein of a prostate acid phosphatase-granulocyte-macrophage colony stimulating factor (PAP-GM-CSF), and can be used for purifying the PAP or the PAP-GM-CSF (Prostate acid phosphatase-granulocyte-macrophage colony stimulating factor), so that the anti-PAP antibody disclosed by the invention can be used for purifying the PAP or the PAP-GM-CSF (Prostate acid phosphatase-granulocyte-macrophage colony stimulating factor) and can be used for purifying the PAP or the PAP-GM-CSF (Prostate acid phosphatase-granulocyte-macrophage colony stimulating factor). Meanwhile, the kit can also be used for diagnosis and treatment of prostatic cancer.

The signals that determine important characteristics of prostate cancer, such as loss of dependence on androgens are described. A key protein, prostatic acid phosphatase, is shown to fold in different ways in response to cellular signals, and the conformer “mix” of this protein in prostatic cells may represent a fundamental difference between normal cells and cancer cells.

A nucleic acid molecule comprising at least one nucleotide sequence encoding SEQ ID NO: 14, 15, 19, 41, or a sequence that is at least about 95% identical thereto; a composition comprising same and a method of administering same to induce an immune response; a polypeptide consisting of SEQ ID NO: 14, 15, 19, 41, or a sequence that is at least about 95% identical thereto; a composition comprising same and a method of administering same to induce an immune response; a composition comprising APC, which have been exposed to the polypeptide, and a method of administering same to treat prostate cancer; a composition comprising T-cells, which are specific for an epitope in a polypeptide consisting of SEQ ID NO: 14, 15, 19, or 41 and a method of administering same to treat prostate cancer; a composition comprising an anti-idiotypic antibody having an internal image of an epitope of a polypeptide consisting of SEQ ID NO: 14, 15, 19, or 41 and a method of administering same to treat prostate cancer; and an immortal B-cell line that produces an anti-idiotypic monoclonal antibody having an internal image of an epitope of a polypeptide consisting of SEQ ID NO: 14, 15, 19, or 41.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Prostatic acid phosphatase, Lactotransferrin, Soluble erythropoietin receptor, Von Willebrand factor, Soluble endothelial protein C receptor, and Beta-2-glycoprotein 1 as diagnostic and prognostic biomarkers in renal injuries.